Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 105, Issue 6, 2008, Pages

  Treister, Nathaniel S ^a,d   Richardson, Paul ^b,e   Schlossman, Robert ^b,e   Miller, Kenneth ^c,e   Woo, Sook Bin ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; BONE NECROSIS; BONE TUMOR; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MALE; MIDDLE AGED; MOUTH ULCER; MULTIPLE MYELOMA; QUALITY OF LIFE; TONGUE DISEASE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MANDIBULAR DISEASES; MIDDLE AGED; MULTIPLE MYELOMA; ORAL ULCER; OSTEONECROSIS; QUALITY OF LIFE; TONGUE DISEASES; TRIAMCINOLONE ACETONIDE;

EID: 43249086403     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2008.02.010     Document Type: Article

References (12)

1. Ruggiero S.L., and Mehrotra B. Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
2. Marx R.E., and Sawatari Y. Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567-1575
3. Woo S.B., Hellstein J.W., and Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
4. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369-376
5. Berenson J.R., Hillner B.E., Kyle R.A., Anderson K., et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736
6. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10 (2005) 52-62
7. Lipton A., Small E., Saad F., Gleason D., Gordon D., Smith M., et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2 20 Suppl (2002) 45-54
8. American Cancer Society. Cancer Facts and Figures 2007 (2007), ACS, Atlanta
9. Mavrokokki T., Cheng A., Stein B., and Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415-423
10. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
11. Treister N., and Woo S.B. Images in clinical medicine. Bisphosphonate-associated osteonecrosis of the jaw. N Engl J Med 355 (2006) 2348
12. Doyle C., Kushi L.H., Byers T., Courneya K.S., Demark-Wahnefried W., Grant B., et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 56 (2006) 323-353